Form 4: Kraig Biocraft Laboratories CEO Acquires 27,500 Shares of Common Stock
SEC Form 4 Filing
Kimberly Kraig Thompson, CEO of Kraig Biocraft Laboratories, Inc., acquired 27,500 shares of common stock at a price of $0.0906 per share on March 31, 2025.
Summary
- On March 31, 2025, Kimberly Kraig Thompson, the CEO of Kraig Biocraft Laboratories, Inc., acquired 27,500 shares of the company's common stock.
- The purchase price was $0.0906 per share.
- Following this transaction, Thompson directly owns 201,677,922 shares of Kraig Biocraft Laboratories, Inc.
Sentiment
Score: 6
Explanation: Neutral sentiment as it's a standard disclosure of stock acquisition by the CEO. The purchase itself could be seen as slightly positive, but the document is primarily informational.
Positives
- The CEO's purchase of shares could be interpreted as a sign of confidence in the company's future prospects.
Industry Context
This type of transaction is common and is required to be reported to the SEC.
Stakeholder Impact
- The CEO's stock purchase may have a minor positive impact on shareholder sentiment.
Key Dates
| Date | Description |
|---|---|
| 03/31/2025 | Date of transaction: CEO acquired 27,500 shares of common stock. |
| 04/10/2025 | Date of signature on the Form 4 filing. |
Keywords
Kraig Biocraft Laboratories, KBLB, Kimberly Kraig Thompson, CEO, stock acquisition, Form 4, beneficial ownership, common stock
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.